Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | UBE2N | P61088 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10875775 | 0.79 | — | — | |
| SCHEMBL7106575 | 0.77 | ALDH1A1 (0.38) | — | |
| SCHEMBL7104570 | 0.74 | — | — | |
| SCHEMBL9430761 | 0.73 | FDPS (0.31) | FDPS | |
| SCHEMBL28114213 | 0.72 | TDP1 (0.38) | LMNAKDM4ETSHRFDPSTDP1 | |
| SCHEMBL2567591 | 0.71 | FDPS (0.36) | FDPS | |
| SCHEMBL3848945 | 0.70 | — | — | |
| L-Alaninol SCHEMBL8676298 | 0.68 | — | — | |
| L-Alaninol SCHEMBL2804901 | 0.67 | TSHR (0.54) | CYP2D6SPHK1GMNNLMNAPOLB | |
| L-Alaninol SCHEMBL1331749 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3476851-A1 | POLYCYCLIC AMINOSILANE COMPOUNDS AND MAKING METHOD | Shin-Etsu Chemical Co., Ltd. (JP) | 2019-05-01 | — | — | EP | disclosed |
| US-20190119308-A1 | POLYCYCLIC AMINOSILANE COMPOUNDS AND MAKING METHOD | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2019-04-25 | — | — | US | disclosed |
| US-10266555-B1 | Polycyclic aminosilane compounds and making method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2019-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119308-A1 | POLYCYCLIC AMINOSILANE COMPOUNDS AND MAKING METHOD | PNMT, BCAT1, PCMT1 | CYP2D6 4835/4885SPHK1 3655/4885GMNN 275/4885 |
| US-10266555-B1 | Polycyclic aminosilane compounds and making method | PNMT, BCAT1, PCMT1 | CYP2D6 4835/4885SPHK1 3655/4885GMNN 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.